Back to Dashboard








Vertex Pharmaceuticals Incorpor (VRTX)
Real-time intraday values
Market Overview
From:
To:
VRTX Intraday
No data available
SymbolVRTX
IPO DateJul 24, 1991
CEODr. Jeffrey Marc Leiden M.D., Ph.D.
Full Time Employees6.4k
SectorHealthcare
IndustryBiotechnology
CountryUnited States
ExchangeNasdaqGS
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Performance
| Period | Return % | Value Change |
|---|---|---|
| 1 Day | -1.11% | -5.76 US$ |
| 5 Days | -4.40% | -23.70 US$ |
| 1 Month | -1.84% | -9.63 US$ |
| 6 Months | +18.50% | +80.38 US$ |
Analyzing Market with AI
Evaluating the last 30 days of history and fundamental metrics of VRTX...
Key Statistics
Market Cap
130.58B
P/E Ratio
33.14
Div Yield
0.00%
52W High
$568.67
52W Low
$412.27
Analyst Consensus
ConsensusBuy
Bullish2681.3%
Neutral515.6%
Bearish13.1%
52W Analyst Price Targets
Min Target
$350.00
$350.00
Max Target
$725.00
$725.00
Current$514.89
Avg Target$595.36
Analyst Recommendations
Target Price:$595.36($350.00 - $725.00)
Looking for more stocks? Explore them in the screener
Community Thoughts
Share your analysis and sentiment on VRTX
Join the community to share your analysis
Latest News for VRTX

Is It Too Early To Buy Insmed Stock?
Trefis•Nov 20, 2026, 02:29 PM

Has Vertex Stock Become A Different Bet?
Trefis•Nov 20, 2026, 12:28 PM

2 Growth Stocks to Buy in November Without Any Hesitation
Motley Fool•Nov 19, 2026, 06:03 PM

Genomics, Vertex extend drug discovery alliance in $220m deal
Pharmaceutical Technology•Nov 19, 2026, 10:53 AM

Should You Pick Vertex Stock Over Its Biotech Rivals?
Trefis•Nov 18, 2026, 05:13 PM

The Women’s Edge and The Boston Globe Again Name CCC to Top 100 Women-Led Businesses in Massachusetts List
GlobeNewswire•Nov 18, 2026, 01:30 PM
iShares Biotechnology ETF (IBB) Buys $16.2 Million More Gilead on Nov. 16
GuruFocus.com•Nov 18, 2026, 11:05 AM
Capital Group Growth (CGGR) Buys $56.4 Million More Cloudflare on Nov. 16
GuruFocus.com•Nov 18, 2026, 11:05 AM

Genomics Ltd. Announces Extension of Strategic Drug Discovery Collaboration with Vertex Pharmaceuticals
PR Newswire•Nov 18, 2026, 09:43 AM

Genomics Ltd. Announces Extension of Strategic Drug Discovery Collaboration with Vertex Pharmaceuticals
PR Newswire•Nov 18, 2026, 09:29 AM